Genfit S.A. (GNFT)
Automate Your Wheel Strategy on GNFT
With Tiblio's Option Bot, you can configure your own wheel strategy including GNFT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GNFT
- Rev/Share 2.1883
- Book/Share 1.3931
- PB 2.3545
- Debt/Equity 0.8976
- CurrentRatio 1.2342
- ROIC 0.2295
- MktCap 163308379.8723
- FreeCF/Share -0.9792
- PFCF -3.3565
- PE 4.3548
- Debt/Assets 0.4103
- DivYield 0
- ROE 0.4511
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution n°28 which was rejected in accordance with the recommendations of the Board of Directors.
Read More
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2024 Universal Registration Document with the Autorité des marches financiers (AMF ; filing n° D.25-0331) and its Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission (SEC).
Read More
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs holders and the convening of the general meeting of the 2025 OCEANEs holders for March 10, 2025.
Read More
About Genfit S.A. (GNFT)
- IPO Date 2019-03-27
- Website https://www.genfit.com
- Industry Biotechnology
- CEO Mr. M. Pascal Prigent
- Employees 180